DE602007005366D1 - Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen - Google Patents

Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen

Info

Publication number: DE602007005366D1
Authority: DE; Germany
Prior art keywords: malignomes; compositions; cell; treatment; cells
Prior art date: 2006-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602007005366T

Other languages

English (en)

Inventor

Claude Geoffrey Davis

Los Rios Miguel A De

Kenneth J Oh

Timothy L Bullock

Patrick T Johnson

Jacek Ostrowski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chimeros Inc

Original Assignee

Chimeros Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-07

Filing date

2007-04-09

Publication date

2010-04-29

2007-04-09 Application filed by Chimeros Inc filed Critical Chimeros Inc

2010-04-29 Publication of DE602007005366D1 publication Critical patent/DE602007005366D1/de

Status Active legal-status Critical Current

2027-04-10 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/80—Nucleic acid, e.g. DNA or RNA
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Botany (AREA)
Zoology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nanotechnology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Obesity (AREA)

DE602007005366T 2006-04-07 2007-04-09 Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen Active DE602007005366D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US79032106P	2006-04-07	2006-04-07
PCT/US2007/008938 WO2008108776A1 (en)	2006-04-07	2007-04-09	Compositions and methods for treating b- cell malignancies

Publications (1)

Publication Number	Publication Date
DE602007005366D1 true DE602007005366D1 (de)	2010-04-29

Family

ID=38537754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602007005366T Active DE602007005366D1 (de)	2006-04-07	2007-04-09	Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen

Country Status (8)

Country	Link
US (1)	US8067011B2 (de)
EP (1)	EP2018156B1 (de)
JP (1)	JP2009533350A (de)
AT (1)	ATE460922T1 (de)
AU (1)	AU2007348315A1 (de)
CA (1)	CA2648581A1 (de)
DE (1)	DE602007005366D1 (de)
WO (1)	WO2008108776A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7964196B2 (en) *	2004-05-25	2011-06-21	Chimeros, Inc.	Self-assembling nanoparticle drug delivery system
DE602007005366D1 (de)	2006-04-07	2010-04-29	Chimeros Inc	Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
KR101456728B1 (ko) *	2006-09-08	2014-10-31	메디뮨 엘엘씨	인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US20090226525A1 (en) *	2007-04-09	2009-09-10	Chimeros Inc.	Self-assembling nanoparticle drug delivery system
WO2010120874A2 (en)	2009-04-14	2010-10-21	Chimeros, Inc.	Chimeric therapeutics, compositions, and methods for using same
US9617343B2 (en)	2009-05-13	2017-04-11	Genzyme Corporation	Methods and compositions for treating lupus
WO2011160206A1 (en)	2010-06-23	2011-12-29	Morin Ryan D	Biomarkers for non-hodgkin lymphomas and uses thereof
US20130195843A1 (en) *	2010-06-23	2013-08-01	British Columbia Cancer Agency Branch	Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
EP2747774A4 (de)	2011-09-09	2015-02-11	Biomed Realty L P	Verfahren und zusammensetzungen zur kontrolle einer virusproteinassemblierung
WO2014116730A2 (en) *	2013-01-23	2014-07-31	The Board Of Trustees Of The Leland Stanford Junior University	Stabilized hepatitis b core polypeptide
EP3152233A1 (de) *	2014-05-08	2017-04-12	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Verwendung einer gegen b-zellen gerichteten antigen-igg-fusion als tolerogene proteintherapie zur behandlung unerwünschter immunreaktionen
WO2020139843A1 (en) *	2018-12-28	2020-07-02	The Board Of Trustee Of The Leland Stanford Junior University	Engineered hepatitis b core polypeptide

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816564A (en) *	1986-01-31	1989-03-28	Merck & Co., Inc.	Method for producing hepatitis B virus proteins in yeast
NZ228948A (en) *	1988-05-13	1991-06-25	Phillips Petroleum Co	Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
WO1992003537A1 (en) *	1990-08-15	1992-03-05	Therion Biologics Corporation	Self-assembling replication defective hybrid virus particles
WO1993000103A1 (en) *	1991-06-21	1993-01-07	The Wistar Institute Of Anatomy And Biology	Chimeric envelope proteins for viral targeting
US6537579B1 (en) *	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
CA2155947C (en) *	1993-02-22	2007-08-21	Mark W. Grinstaff	Methods for in vivo delivery of biologics and compositions useful therefor
US6096331A (en) *	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) *	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) *	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1995024929A2 (en) *	1994-03-15	1995-09-21	Brown University Research Foundation	Polymeric gene delivery system
AU2520595A (en) *	1994-05-31	1995-12-21	Inex Pharmaceuticals Corp.	Virosome-mediated intracellular delivery of therapeutic agents
US6204059B1 (en) *	1994-06-30	2001-03-20	University Of Pittsburgh	AAV capsid vehicles for molecular transfer
US6613749B1 (en) *	1994-07-26	2003-09-02	Imperial College Innovations Limited	Papovavirus pseudocapsids and use thereof for exogenous material transfer
US5846782A (en)	1995-11-28	1998-12-08	Genvec, Inc.	Targeting adenovirus with use of constrained peptide motifs
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997000326A1 (en) *	1995-06-15	1997-01-03	Introgene B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
IL124654A0 (en)	1995-11-28	1998-12-06	Genvec Inc	Vectors and method for gene transfer to cells
US6284494B1 (en) *	1995-12-12	2001-09-04	The University Of British Columbia	Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
WO1997037680A1 (en) *	1996-04-05	1997-10-16	The Board Of Trustees Of The University Of Illinois	Macromolecular complexes for drug delivery
FR2749323B1 (fr) *	1996-06-04	1998-07-10	Pasteur Merieux Serums Vacc	Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
EP0969863A4 (de) *	1996-09-18	2001-11-07	Univ Texas	Defekte virale störpartikel und deren verwendung.
AU738585B2 (en) *	1996-11-08	2001-09-20	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Synthesis and purification of hepatitis C virus-like particles
US6180389B1 (en) *	1997-01-03	2001-01-30	The Research And Development Institute, Inc.	Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
CA2318981A1 (en)	1998-02-09	1999-08-12	Genzyme Corporation	Nucleic acid delivery vehicles
CN100387622C (zh) *	1998-02-12	2008-05-14	免疫合成物公司	策略性修饰的乙肝核心蛋白及其衍生物
EP1024502A4 (de) *	1998-08-05	2001-10-24	Sony Corp	Elektrolytzusammensetzung, elektrolyt und verfahren zu ihrer herstellung, und diese enthaltende zelle
WO2000009158A1 (en)	1998-08-12	2000-02-24	University Of Virginia Patent Foundation	Assay for assembly of herpes simplex virus capsid
US6759237B1 (en) *	1998-11-05	2004-07-06	The Trustees Of The University Of Pennsylvania	Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1845163A3 (de)	1998-11-05	2007-10-31	The Trustees Of The University Of Pennsylvania	Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
EE200100292A (et) *	1998-12-04	2002-08-15	Biogen, Inc.	Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
US6710173B1 (en) *	1999-06-25	2004-03-23	Progenics Pharmaceuticals, Inc.	Stabilized viral envelope proteins and uses thereof
ATE362990T1 (de)	1999-06-30	2007-06-15	Evotec Ag	Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
US20020064520A1 (en) *	1999-08-19	2002-05-30	Yanina Rozenberg	Targeted artificial gene delivery
US6602932B2 (en) *	1999-12-15	2003-08-05	North Carolina State University	Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
US6616944B2 (en) *	2000-03-08	2003-09-09	Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh	Self-assembling colloidal carriers for protein delivery
US7332337B2 (en) *	2000-05-16	2008-02-19	Galapagos Nv	Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
EP2060267A3 (de) *	2000-07-19	2009-08-05	The Regents Of The University Of California	Verfahren zur Behandlung einer neurodegenerativen Erkrankung des Gehirns
US6696038B1 (en) *	2000-09-14	2004-02-24	Expression Genetics, Inc.	Cationic lipopolymer as biocompatible gene delivery agent
CZ308053B6 (cs) *	2000-12-01	2019-11-27	Max Planck Gesellschaft	Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
WO2002044204A2 (en)	2000-12-01	2002-06-06	The Government Of The United States, As Represented By The Secretary Of Health And Human Services	Cell-free assembly of lentiviral capsids
DE60037263T2 (de)	2000-12-29	2008-10-09	Evotec Ag	Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
EP1409748B1 (de) *	2001-06-22	2011-10-26	The Trustees of The University of Pennsylvania	Rekombinante Adenoviren mit Affen-Adenovirus Proteinen und Verwendung davon.
US7101995B2 (en) *	2001-08-27	2006-09-05	Mirus Bio Corporation	Compositions and processes using siRNA, amphipathic compounds and polycations
EP1461079B8 (de) *	2001-09-06	2012-03-14	Progenics Pharmaceuticals, Inc.	Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung
MXPA04004876A (es) *	2001-11-21	2004-07-30	Univ Pennsylvania	Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
EP1944043A1 (de)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
JP4810062B2 (ja) *	2001-12-17	2011-11-09	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	アデノ随伴ウイルス（ａａｖ）血清型８の配列
JP4598519B2 (ja) *	2002-06-20	2010-12-15	サイトスバイオテクノロジーアーゲー	アジュバントとして使用するためのパッケージ化されたウィルス様粒子：調製法及び使用法
EP1447079A1 (de) *	2003-02-15	2004-08-18	Fraunhofer-Gesellschaft für angewandte Forschung e.V.	Vesikel mit chimären Rezeptoren zur Induktion einer gerichteten T-Zellantwort in vivo
CA2505520C (en) *	2002-11-06	2012-07-17	Azaya Therapeutics, Inc.	Protein-stabilized liposomal formulations of pharmaceutical agents
JP2004175665A (ja)	2002-11-22	2004-06-24	Japan Science & Technology Agency	タンパク質中空ナノ粒子およびそれを用いた薬剤
CN104587479A (zh) *	2002-12-09	2015-05-06	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
US20070178066A1 (en)	2003-04-21	2007-08-02	Hall Frederick L	Pathotropic targeted gene delivery system for cancer and other disorders
WO2005038430A2 (en) *	2003-10-15	2005-04-28	Board Of Regents, The University Of Texas System	Viral fibers
US7964196B2 (en) *	2004-05-25	2011-06-21	Chimeros, Inc.	Self-assembling nanoparticle drug delivery system
US20080131928A1 (en) *	2004-07-01	2008-06-05	Hiroshi Handa	Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
GB0416487D0 (en) *	2004-07-23	2004-08-25	Isis Innovation	Modified virus
JP2008512484A (ja) *	2004-09-09	2008-04-24	ザジェネラルホスピタルコーポレーション	心臓細胞におけるホスファターゼ活性の調節
EP1799251A2 (de) *	2004-09-17	2007-06-27	Chr. Hansen A/S	Chimere von phagen stammende teilchen, verfahren zu ihrer herstellung und verwendung
EP2270136A1 (de)	2004-12-17	2011-01-05	Beth Israel Deaconess Medical Center	Zusammensetzungen für bakteriell vermitteltes Gen-silencing sowie Verfahren zur Verwendung davon
WO2006088229A1 (ja)	2005-02-16	2006-08-24	The Circle For The Promotion Of Science And Engineering	改変されたウイルスカプシドタンパク質及びその使用
US20070258889A1 (en) *	2005-11-09	2007-11-08	Montana State University	Novel nanoparticles and use thereof
US20110104051A1 (en)	2006-03-27	2011-05-05	The Regents Of The University Of California	Chemically Modified Viral Capsids as Targeted Delivery Vectors for Diagnostic and Therapeutic Agents
DE602007005366D1 (de)	2006-04-07	2010-04-29	Chimeros Inc	Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
CN101437538A (zh)	2006-04-28	2009-05-20	宾夕法尼亚州立大学托管会	修饰的腺病毒六邻体蛋白和其应用
WO2008027084A2 (en)	2006-04-28	2008-03-06	The Trustees Of The University Of Pennsylvania	Modified aav vectors having reduced capsid immunogenicity and use thereof
EP2024076A1 (de)	2006-05-22	2009-02-18	Nizo Food Research B.V.	Proteinverkapselte partikel
CA2657648A1 (en)	2006-07-13	2008-01-17	Emory University	Virosomes, methods of preparation, and immunogenic compositions
AU2007286203B2 (en)	2006-08-08	2013-05-02	Board Of Regents, The University Of Texas System	Multistage delivery of active agents
US9803189B2 (en)	2006-08-23	2017-10-31	Stc.Unm	Virus-like platform for rapid vaccine discovery
AU2007302198A1 (en)	2006-09-28	2008-04-03	Cytos Biotechnology Ag	Interleukin-1 muteins linked to virus-like particles to treat IL-1 associated diseases
WO2008051101A1 (en)	2006-10-25	2008-05-02	Universidade De Coimbra	Oral submicron particle delivery system for proteins and process for its production
US20090226525A1 (en) *	2007-04-09	2009-09-10	Chimeros Inc.	Self-assembling nanoparticle drug delivery system

2007
- 2007-04-09 DE DE602007005366T patent/DE602007005366D1/de active Active
- 2007-04-09 AU AU2007348315A patent/AU2007348315A1/en not_active Abandoned
- 2007-04-09 AT AT07873883T patent/ATE460922T1/de not_active IP Right Cessation
- 2007-04-09 JP JP2009504356A patent/JP2009533350A/ja not_active Withdrawn
- 2007-04-09 EP EP07873883A patent/EP2018156B1/de not_active Not-in-force
- 2007-04-09 WO PCT/US2007/008938 patent/WO2008108776A1/en active Application Filing
- 2007-04-09 CA CA002648581A patent/CA2648581A1/en not_active Abandoned
- 2007-04-09 US US11/697,945 patent/US8067011B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2009533350A (ja)	2009-09-17
EP2018156B1 (de)	2010-03-17
ATE460922T1 (de)	2010-04-15
EP2018156A1 (de)	2009-01-28
US8067011B2 (en)	2011-11-29
WO2008108776A1 (en)	2008-09-12
US20070269370A1 (en)	2007-11-22
CA2648581A1 (en)	2008-09-12
AU2007348315A1 (en)	2008-09-12

Publication	Publication Date	Title
DE602007005366D1 (de)	2010-04-29	Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
PH12014500053A1 (en)	2015-03-30	Proteasome inhibitors
ATE510538T1 (de)	2011-06-15	Zusammensetzungen und verfahren für nervenschutz
CY1116435T1 (el)	2017-02-08	Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
MA31874B1 (fr)	2010-11-01	Inhibiteurs de bêta-lactamases
DE602006018583D1 (de)	2011-01-13	Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ME01532B (me)	2014-04-20	Jedinjenja
MX2012002542A (es)	2012-04-02	Compuestos y composiciones como inhibidores de cinasa de proteina.
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
TW200733976A (en)	2007-09-16	Method for the treatment of cognitive dysfunction
ATE512948T1 (de)	2011-07-15	Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
TW200734334A (en)	2007-09-16	Treatment of substance abuse
CY1115725T1 (el)	2017-01-25	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
ATE462438T1 (de)	2010-04-15	Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
MA32841B1 (fr)	2011-11-01	Composés de cycloundeca depsipeptides et leur utilisation comme médicament
ATE539754T1 (de)	2012-01-15	Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
ATE466841T1 (de)	2010-05-15	1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
UA104880C2 (uk)	2014-03-25	Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
DE602004031356D1 (de)	2011-03-24	Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
DE602006012313D1 (de)	2010-04-01	Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
DE102004016179A1 (de)	2005-10-20	Verbindungen zur Behandlung von proliferativen Prozessen
ATE474574T1 (de)	2010-08-15	Imidazoazephinonverbindungen

Legal Events

Date	Code	Title	Description
2011-04-07	8364	No opposition during term of opposition